TNKS1/2 proteins are key players in the regulation of WNT/β-catenin and Hippo signaling pathways, which are implicated in various diseases, including cancer, immune evasion and fibrosis. Consequently, ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into phase 2. The Waltham, Massachusetts-based company already unveiled ...

The development of antifibrotic drugs that target fibrosis-related pathways is one of the most important areas of innovation. Galectin-3 inhibitors, TGF-β inhibitors, and CCR2/CCR5 antagonists have ...

A. Cure the primary disease. The most effective way to eliminate hepatic fibrosis is to clear the primary cause of liver disease. The latter includes abstinence in the case of alcoholic liver ...

and PARP inhibitors), immunomodulators {autoimmune diseases, cancers}, anti-inflammatory drugs {asthma, COPD}, gene modulators [e.g., CFTR modulators in cystic fibrosis]), by Route Of ...

The clarification of the mechanisms of fibrosis has led to a surge in enthusiasm for treating hepatic fibrosis, and animal models strongly support the rationale of this approach. In fact ...

inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). In May 2024, Alentis Therapeutics announced that the US Food and Drug Administration (FDA) had granted lixudebart (ALE.F02 ...

(MENAFN- GlobeNewsWire - Nasdaq) The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging ...